Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 172.06B |
| Revenue (ttm) | 54.17B |
| Net Income (ttm) | 13.97B |
| Shares Out | n/a |
| EPS (ttm) | 5.52 |
| PE Ratio | 12.32 |
| Forward PE | 8.80 |
| Dividend | 2.91 (4.14%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 4,162 |
| Average Volume | 2,745 |
| Open | 70.20 |
| Previous Close | 71.80 |
| Day's Range | 68.80 - 70.50 |
| 52-Week Range | 65.50 - 107.40 |
| Beta | 0.38 |
| RSI | 43.28 |
| Earnings Date | Oct 30, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
How the UK fell out with big pharma
The U.K. is in the midst of a falling out with big pharma over drug pricing. Merck has walked away from a 1 billion facility in London and pulled its research activities altogether. Now Eli Lilly, San...
Guru Fundamental Report for MRK - Peter Lynch
Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter...
Astra, Lilly are latest to reevaluate U.K. investments after Merck’s pullback: reports
Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs
The U.K. faces a growing risk of losing pharmaceutical investment. That’s according to Oxford professor John Bell , a scientist who was involved in coordinating government and industry efforts during ...
AstraZeneca follows Merck’s pullback in Britain: report
UK government must heed warns over big pharma investment
New ventures are lifeblood of life sciences, and Merck’s move to scrap its £1bn London research centre suggests mood hardening Compare and contrast. Here is the opening line in the government’s respon...
Merck's Capvaxive Vaccine Achieves Promising Results in Pediatric Trial (MRK)
Merck's Capvaxive Vaccine Achieves Promising Results in Pediatric Trial (MRK)
Merck (MRK) Reports Successful Phase 3 Trial Results for Pneumococcal Vaccine
Merck (MRK) Reports Successful Phase 3 Trial Results for Pneumococcal Vaccine
Merck's pneumococcal shot shows promise in children and teens in study
Merck's pneumococcal vaccine showed strong immune responses in children and teens at higher risk of serious illness in a late-stage study, the drugmaker said.
Merck’s move to axe £1bn UK expansion was ‘commercial decision’, says minister
The Conservatives said Merck’s decision should send alarm bells ringing across Government.
Merck says trial data for pneumonia shot Capvaxive shows promise in younger people
Merck's pneumonia shot shows promise in late-stage study
Drugmaker Merck said on Thursday that its pneumonia shot showed strong immune responses in children and teens who are at higher risk of serious illness, based on results from a late-stage study presen...
CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 STRIDE-13 trial evaluating CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccin...
CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--CAPVAXIVE Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease.
Big pharma will halt investments in UK, warns eminent scientist Sir John Bell
Warning follows news of US drugmaker Merck’s decision to scrap planned £1bn London research centre Sir John Bell, a prominent scientist who brought business and government together during the Covid-19...
Britain defends investment record as Merck scraps labs over pharma environment
Britain defended its record on attracting investment on Thursday after U.S. drugmaker Merck said it was abandoning a new London research centre and a top industry lobby group warned a challenging busi...
Merck scraps £1bn London expansion as report warns UK drugs sector ‘losing out’
UK pharmaceutical sector ‘risks losing investment to other countries’.
Merck (MRK) Scraps £1B Research Center Project in London, Lays Off Over 100 Scientists
Merck (MRK) Scraps £1B Research Center Project in London, Lays Off Over 100 Scientists
US drugmaker scraps plans for £1bn UK research centre
Merck criticises ‘successive UK governments’ as it cancels King’s Cross development
Merck (MRK) Reconsiders UK Plans, Relocates Research Operations
Merck (MRK) Reconsiders UK Plans, Relocates Research Operations
Merck (MRK) Shuts Down London R&D Due to Challenging UK Business Environment
Merck (MRK) Shuts Down London R&D Due to Challenging UK Business Environment
Merck to cancel London drug research center, lay off scientists : FT
US drugmaker Merck scraps £1bn London research centre and cuts 125 science jobs
New blow to UK’s key life science sector as industry body warns country is losing ground on investment and research US drugmaker Merck has scrapped a £1bn London research centre and is laying off 125 ...
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...
Merck to scrap London drug research centre
Merck said on Wednesday it was scrapping research operations in London, citing the UK's challenging business environment.